Gara Jalqabaatti › Luukemiya Limfoositiikii Keessummaa › North Carolina › Charlotte
Qorannoo klinikaalii Luukemiya Limfoositiikii Keessummaa Charlotte, NC keessatti
Qorannoo 9 Luukemiya Limfoositiikii Keessummaa f Charlotte fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Charlotte
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 3
- Atrium Health Levine Cancer Institute (Lci), Charlotte
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Namoota walitti qabaa jiraSadarkaa 3
- Levine Cancer Center, Charlotte
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Namoota walitti qabaa jiraSadarkaa 3
- Atrium Health Levine Cancer Institute (Lci), Charlotte
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Namoota walitti qabaa jiraSadarkaa 3
- Carolina Oncology Specialists, PA ( Site 0054), Charlotte
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Charlotte
- Research Site, Charlotte
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Namoota walitti qabaa jiraSadarkaa 2
- Research Site, Charlotte
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Namoota walitti qabaa jiraSadarkaa 3
- Atrium Health /ID# 267219, Charlotte
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Namoota walitti qabaa jiraSadarkaa 2
- Novant Health Presbyterian Medical Center /ID# 230201, Charlotte
Qorannoo Luukemiya Limfoositiikii Keessummaa magaalota biroo keessatti
- Boston, MAQorannoo 31
- Columbus, OHQorannoo 28
- Durham, NCQorannoo 27
- Washington, DCQorannoo 22
- Seattle, WAQorannoo 20
- Rochester, MNQorannoo 18
- New York City, NYQorannoo 18
- Houston, TXQorannoo 17
- Baldwin Park, CAQorannoo 16
- Milwaukee, WIQorannoo 15
- Chicago, ILQorannoo 14
- Cincinnati, OHQorannoo 14
Qorannoo biroo Charlotte keessatti
- Saree (Gosoota Hunda)Qorannoo 27
- Saree OljooQorannoo 22
- Myeloma Baay’eeQorannoo 21
- Kansara Qara'a Non-Small CellQorannoo 19
- Leukemia Myeloidii HamaaQorannoo 16
- ObesityQorannoo 16
- Baayyee UlfaataaQorannoo 15
- Kansarii ColorectalQorannoo 13
- Kansarii OvariiQorannoo 12
- Cufama OnneeQorannoo 11
- Kansara MetastatikiiQorannoo 11
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 10
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.